Living Cell Technologies Limited (LVCLY)
Living Cell Technologies Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.03, up 24.39% on the session, giving a market capitalisation of $11.4M. On trailing twelve-month figures it carries a trailing P/E of -11.54, a net margin of -1673.8%. Its beta of 0.76 implies it has historically moved less than the broad market.
Living Cell Technologies Limited (LCT) is a biotechnology company dedicated to the innovation, development, and market introduction of regenerative medical therapies. These treatments leverage naturally occurring cells with the aim of restoring physiological functions, particularly within New Zealand. A primary focus for LCT is NTCELL, a novel alginate-coated capsule currently progressing through Phase IIb clinical trials for its application in treating Parkinson's disease. The company was founded in 1987 and operates from its base in Sydney, Australia.
Living Cell Technologies Limited is most often compared with the following Healthcare names: